Advances in modern medicine have dramatically improved our ability to treat various diseases. But some life-saving drugs also cause adverse reactions that can be severe and debilitating.
We know that genetics is a key determinant in these adverse drug reactions. Dr. Britt Drögemöller, Canada Research Chair in Pharmacogenomics and Precision Medicine, is working on new computational methods to reveal the genetics behind non-optimal treatment outcomes in vulnerable and under-studied populations. She and her research team are developing more accurate predictors of adverse outcomes and using genomics-guided analyses to identify drugs that may be used to prevent these adverse reactions.